6580.TWO TaiRx, Inc.

Healthcare Biotechnology Taiwan OTC Exchange
11.10 TWD
Close of Nov 6, 2026
9.99 23.60
Market cap
TWD 1.24B
P/E
-
P/B
3.61x
ROE
-50.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6580.TWO undervalued?

Graham number

The Graham number of TaiRx, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TaiRx, Inc. fundamental analysis

No fundamental analysis for TaiRx, Inc. yet.

TaiRx, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TaiRx, Inc.

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of sele…

Full company profile